|
CA1247080A
(en)
|
1983-03-08 |
1988-12-20 |
Commonwealth Serum Laboratories Commission |
Antigenically active amino acid sequences
|
|
IL86278A
(en)
*
|
1988-05-04 |
2003-06-24 |
Yeda Res & Dev |
Endowing cells with antibody specificity using chimeric t cell receptor
|
|
US5906936A
(en)
*
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
EP1958962A3
(en)
|
1997-06-12 |
2013-05-01 |
Novartis International Pharmaceutical Ltd. |
Artificial antibody polypeptides
|
|
TWI224995B
(en)
|
1998-03-19 |
2004-12-11 |
Ciba Sc Holding Ag |
Stabilization of wood substrates
|
|
WO2002088170A2
(en)
|
2001-04-26 |
2002-11-07 |
Biogen, Inc. |
Cripto blocking antibodies and uses thereof
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
WO2003020763A2
(en)
|
2001-08-31 |
2003-03-13 |
Avidex Limited |
Soluble t cell receptor
|
|
US7192586B2
(en)
|
2001-09-20 |
2007-03-20 |
Cornell Research Foundation, Inc. |
Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen
|
|
US20050123536A1
(en)
|
2001-11-20 |
2005-06-09 |
Che-Leung Law |
Treatment of immunological disorders using anti-dc30 antibodies
|
|
US6992176B2
(en)
|
2002-02-13 |
2006-01-31 |
Technion Research & Development Foundation Ltd. |
Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
|
|
AU2003216341A1
(en)
|
2002-02-20 |
2003-09-09 |
Dyax Corporation |
Mhc-peptide complex binding ligands
|
|
NZ539225A
(en)
|
2002-10-09 |
2006-09-29 |
Avidex Ltd |
Single chain recombinant T cell receptors
|
|
GB0304068D0
(en)
*
|
2003-02-22 |
2003-03-26 |
Avidex Ltd |
Substances
|
|
CU23403A1
(es)
|
2003-04-23 |
2009-08-04 |
Centro Inmunologia Molecular |
Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
|
|
US7709610B2
(en)
|
2003-05-08 |
2010-05-04 |
Facet Biotech Corporation |
Therapeutic use of anti-CS1 antibodies
|
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
|
EP1756278B1
(en)
|
2004-05-19 |
2008-09-17 |
MediGene Ltd. |
Method of improving t cell receptors
|
|
ATE417065T1
(de)
|
2004-05-19 |
2008-12-15 |
Medigene Ltd |
Hochaffiner ny-eso-t-zellen-rezeptor
|
|
WO2005118788A2
(en)
|
2004-05-27 |
2005-12-15 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
EP1612224B1
(en)
|
2004-06-29 |
2012-03-07 |
B.R.A.H.M.S GmbH |
Novel monoclonal thyroid stimulating or blocking antibodies, peptide sequences corresponding to their variable regions, and their uses in diagnostic, preventive and therapeutic medicine
|
|
EP1846454A2
(en)
|
2004-09-30 |
2007-10-24 |
Medarex, Inc. |
Human monoclonal antibodies to fc gamma receptor ii (cd32)
|
|
MX2007003910A
(es)
*
|
2004-10-01 |
2007-06-07 |
Avidex Ltd |
Receptores de celulas t que contienen un enlace entre cadenas bisulfuro no nativo ligado a agentes terapeuticos.
|
|
EP2305716B1
(en)
|
2004-11-30 |
2014-10-22 |
Celldex Therapeutics, Inc. |
Antibodies directed to gpnmb and uses thereof
|
|
AU2006203889A1
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
CRIPTO binding molecules
|
|
DOP2006000029A
(es)
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
|
KR20080032097A
(ko)
|
2005-06-20 |
2008-04-14 |
메다렉스, 인코포레이티드 |
씨디19 항체 및 그의 용도
|
|
CN101360761B
(zh)
|
2005-12-08 |
2012-09-12 |
米德列斯公司 |
抗蛋白质酪氨酸激酶7（ptk7）的人单克隆抗体及其用途
|
|
JP5512128B2
(ja)
|
2005-12-08 |
2014-06-04 |
メダレックス・リミテッド・ライアビリティ・カンパニー |
フコシルｇｍ１に対するヒトモノクローナル抗体および抗フコシルｇｍ１を使用するための方法
|
|
DK2270050T3
(da)
|
2005-12-30 |
2013-08-12 |
Merck Patent Gmbh |
Anti-CD19-antistoffer med nedsat immunogenicitet
|
|
US20080131428A1
(en)
|
2006-02-24 |
2008-06-05 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
|
EP2540741A1
(en)
|
2006-03-06 |
2013-01-02 |
Aeres Biomedical Limited |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
US8524865B2
(en)
|
2006-05-30 |
2013-09-03 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
|
MX2009002414A
(es)
|
2006-09-08 |
2009-05-20 |
Medimmune Llc |
Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
|
|
CN105998028A
(zh)
|
2007-02-22 |
2016-10-12 |
科尔比制药公司 |
羟胺化合物及其用法
|
|
EP2014302A1
(en)
|
2007-07-12 |
2009-01-14 |
Institut Curie |
An antibody specific for the Tn antigen for the treatment of cancer
|
|
EP2186825A1
(en)
*
|
2008-11-13 |
2010-05-19 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Human-derived T cell receptors
|
|
UA109633C2
(uk)
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
|
JP2012517806A
(ja)
|
2009-02-16 |
2012-08-09 |
バイオレックス・セラピューティクス インコーポレイテッド |
ヒト化抗ｃｄ２０抗体および使用方法
|
|
EP2398829A2
(en)
|
2009-02-23 |
2011-12-28 |
Glenmark Pharmaceuticals S.A. |
Humanized antibodies that bind to cd19 and their uses
|
|
CA2755686A1
(en)
|
2009-03-16 |
2010-09-23 |
Daniel A. Vallera |
Methods and compositions for bi-specific targeting of cd19/cd22
|
|
MA33276B1
(fr)
|
2009-04-20 |
2012-05-02 |
Oxford Biotherapeutics Ltd |
Anticorps spécifiques à la cadhérine-17
|
|
WO2011009090A1
(en)
|
2009-07-16 |
2011-01-20 |
Xoma Technology Ltd. |
Antibodies to high molecular weight melanoma associated antigen
|
|
CA3031851C
(en)
|
2009-10-23 |
2020-07-07 |
Amgen British Columbia |
Anti-gcc antibody molecules and related compositions and methods
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
US20120269814A1
(en)
|
2009-11-10 |
2012-10-25 |
Amgen Inc. |
Anti-c mpl antibodies
|
|
HUE032519T2
(en)
|
2010-03-26 |
2017-09-28 |
Memorial Sloan Kettering Cancer Center |
Antibodies to muc16 and methods of use thereof
|
|
EP3165533B1
(en)
|
2010-05-11 |
2020-04-08 |
Fred Hutchinson Cancer Research Center |
Chlorotoxin variants, conjugates and methods for their use
|
|
RU2012149227A
(ru)
|
2010-05-20 |
2014-06-27 |
Аблинкс Нв |
Биологические материалы, относящиеся к her3
|
|
EP2409993A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC function with improved glycosylation profile
|
|
US9163258B2
(en)
|
2010-07-23 |
2015-10-20 |
Fred Hutchinson Cancer Research Center |
Method for the treatment of obesity
|
|
AR082641A1
(es)
|
2010-09-07 |
2012-12-19 |
Imclone Llc |
Composiciones de anticuerpo anti-vegfr-3
|
|
EP2621953B1
(en)
|
2010-09-30 |
2017-04-05 |
Ablynx N.V. |
Biological materials related to c-met
|
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
|
MX2013004792A
(es)
|
2010-10-27 |
2013-08-27 |
Baylor College Medicine |
Receptor cd27 quimericos para redirigir celulas t a malignidades cd70-positivas.
|
|
AU2012236068A1
(en)
|
2011-04-01 |
2013-10-17 |
Eureka Therapeutics, Inc. |
T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
|
|
PE20141045A1
(es)
|
2011-05-27 |
2014-09-10 |
Glaxo Group Ltd |
Proteinas de union a bcma (cd269/tnfrsf17)
|
|
US20140248278A1
(en)
|
2011-06-08 |
2014-09-04 |
The Regents Of The University Of California |
Anti-cd22 antigen binding molecules to treat lung cancer and prostate cancer
|
|
WO2013019730A1
(en)
|
2011-07-29 |
2013-02-07 |
The Washington University |
Antibodies to tip-1 and grp78
|
|
MX354479B
(es)
|
2011-08-16 |
2018-03-07 |
Morphosys Ag |
Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno.
|
|
ES2764105T3
(es)
|
2011-10-17 |
2020-06-02 |
Massachusetts Inst Technology |
Administración intracelular
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
US20130302274A1
(en)
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
|
SMT201700467T1
(it)
|
2012-02-24 |
2017-11-15 |
Abbvie Stemcentrx Llc |
Modulatori di dll3 e metodi di uso
|
|
WO2013130565A1
(en)
|
2012-02-29 |
2013-09-06 |
The Brigham And Women's Hosptial, Inc. |
Neutralizing antibody for epstein barr virus associated disease
|
|
MX2014010987A
(es)
|
2012-03-12 |
2015-03-03 |
Medimmune Llc |
Tratamiento de esclerosis multiple con anticuerpo anti-cd19.
|
|
US9163090B2
(en)
|
2012-05-07 |
2015-10-20 |
Cellerant Therapeutics, Inc. |
Antibodies specific for CLL-1
|
|
WO2013167153A1
(en)
|
2012-05-09 |
2013-11-14 |
Ganymed Pharmaceuticals Ag |
Antibodies useful in cancer diagnosis
|
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
|
HUE064187T2
(hu)
|
2012-05-25 |
2024-02-28 |
Cellectis |
Eljárás immunterápiára alkalmas allogén és immunszupresszív-rezisztens T-sejt módosítására
|
|
WO2014039513A2
(en)
|
2012-09-04 |
2014-03-13 |
The Trustees Of The University Of Pennsylvania |
Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
|
|
WO2014052064A1
(en)
|
2012-09-27 |
2014-04-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
|
US9695228B2
(en)
|
2012-11-21 |
2017-07-04 |
Janssen Biotech, Inc. |
EGFR and c-Met fibronectin type III domain binding molecules
|
|
EP2738180A1
(en)
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
WO2014089354A1
(en)
|
2012-12-07 |
2014-06-12 |
The Regents Of The University Of California |
Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
|
ES2871816T3
(es)
|
2012-12-27 |
2021-11-02 |
Sanofi Sa |
Anticuerpos anti-LAMP1 y conjugados anticuerpo-fármaco, y usos de los mismos
|
|
US9920121B2
(en)
|
2013-01-25 |
2018-03-20 |
Amgen Inc. |
Antibodies targeting CDH19 for melanoma
|
|
MX378463B
(es)
|
2013-02-26 |
2025-03-10 |
Memorial Sloan Kettering Cancer Center |
Composiciones y usos de las mismas para inmunoterapia.
|
|
AU2014225708B2
(en)
|
2013-03-05 |
2018-10-18 |
Baylor College Of Medicine |
Heparanase expression in human T lymphocytes
|
|
US20160017048A1
(en)
|
2013-03-07 |
2016-01-21 |
Baylor College Of Medicine |
Targeting cd138 in cancer
|
|
US9675697B2
(en)
|
2013-03-11 |
2017-06-13 |
The Regents Of The University Of Michigan |
BET bromodomain inhibitors and therapeutic methods using the same
|
|
PL2970492T3
(pl)
|
2013-03-15 |
2019-10-31 |
Univ Wake Forest Health Sciences |
Przeciwciała przeciwko ludzkim i psim il-13ra2
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
WO2014160627A1
(en)
|
2013-03-25 |
2014-10-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
|
|
CN104140974B
(zh)
|
2013-05-08 |
2017-09-29 |
科济生物医药（上海）有限公司 |
编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
|
|
EP3783098A1
(en)
|
2013-05-14 |
2021-02-24 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
SG11201509609SA
(en)
|
2013-05-24 |
2015-12-30 |
Univ Texas |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
WO2014191527A1
(en)
|
2013-05-31 |
2014-12-04 |
Cellectis |
A laglidadg homing endonuclease cleaving the t cell receptor alpha gene and uses thereof
|
|
GB201313377D0
(en)
|
2013-07-26 |
2013-09-11 |
Adaptimmune Ltd |
T cell receptors
|
|
WO2015017755A1
(en)
|
2013-08-02 |
2015-02-05 |
The Regents Of The University Of California |
Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
|
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
|
GB201317929D0
(en)
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
CA2926698C
(en)
|
2013-10-15 |
2021-06-22 |
The California Institute For Biomedical Research |
Chimeric antigen receptor t cell switches and uses thereof
|
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
|
AU2014352638B2
(en)
|
2013-11-25 |
2018-08-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors to control HIV infection
|
|
EP3074025A1
(en)
|
2013-11-27 |
2016-10-05 |
Baylor College Of Medicine |
Csgp4-specific chimeric antigen receptor for cancer
|
|
EP3461845B1
(en)
|
2013-12-13 |
2020-09-16 |
Genentech, Inc. |
Anti-cd33 antibodies and immunoconjugates
|
|
JPWO2015108203A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社オーダーメードメディカルリサーチ |
抗ｓｌｃ６ａ６抗体を用いたがん治療用医薬組成物
|
|
ES2963718T3
(es)
|
2014-01-21 |
2024-04-01 |
Novartis Ag |
Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
|
|
EP3102236A4
(en)
|
2014-02-05 |
2017-08-30 |
The University of Chicago |
Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
|
|
GB201403875D0
(en)
|
2014-03-05 |
2014-04-16 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
ES3033286T3
(en)
|
2014-03-05 |
2025-08-01 |
Autolus Ltd |
Conjugated antibody or bispecific t-cell engager which selectively binds either tcr beta constant region 1 (trbc1) or trbc2
|
|
ES2939760T3
(es)
|
2014-03-15 |
2023-04-26 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico para antígenos
|
|
SI3126381T2
(sl)
|
2014-04-01 |
2022-05-31 |
Biontech Cell&Gene Therapies Gmbh |
Claudin-6-specifični imunoreceptorji in t-celični epitopi
|
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
|
MX382565B
(es)
|
2014-04-25 |
2025-03-13 |
2Seventy Bio Inc |
Receptores de antigenos quimericos del promotor mnd.
|
|
US10301370B2
(en)
|
2014-05-02 |
2019-05-28 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of chimeric autoantibody receptor T cells
|
|
EP2944652A1
(en)
*
|
2014-05-13 |
2015-11-18 |
Technische Universität München |
Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
|
|
EP4609876A2
(en)
*
|
2014-05-29 |
2025-09-03 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Anti-human papillomavirus 16 e7 t cell receptors
|
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
|
JP7054622B2
(ja)
|
2014-07-21 |
2022-04-14 |
ノバルティス アーゲー |
ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
|
|
EP3722316A1
(en)
|
2014-07-21 |
2020-10-14 |
Novartis AG |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
CN107074970B
(zh)
|
2014-08-04 |
2021-07-30 |
弗雷德哈钦森癌症研究中心 |
特异性针对wt-1的t细胞免疫疗法
|
|
US9982045B2
(en)
|
2014-08-12 |
2018-05-29 |
Novartis Ag |
Anti-CDH6 antibody drug conjugates
|
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
|
JP6588084B2
(ja)
|
2014-08-19 |
2019-10-09 |
ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｓｓｅａ４抗原に特異的なキメラ抗原受容体
|
|
ES2688035T3
(es)
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
|
US10093746B2
(en)
|
2014-09-04 |
2018-10-09 |
The Trustees Of The University Of Pennsylvania |
Glypican-3 antibody and uses thereof
|
|
SG11201701599UA
(en)
|
2014-09-05 |
2017-03-30 |
Janssen Pharmaceutica Nv |
Cd123 binding agents and uses thereof
|
|
CA2972714A1
(en)
|
2014-09-09 |
2016-03-17 |
Unum Therapeutics |
Chimeric receptors and uses thereof in immune therapy
|
|
US9751946B2
(en)
|
2014-09-12 |
2017-09-05 |
Genentech, Inc. |
Anti-CLL-1 antibodies and immunoconjugates
|
|
AU2015317370A1
(en)
|
2014-09-19 |
2017-03-23 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors
|
|
US20170281683A1
(en)
|
2014-09-26 |
2017-10-05 |
Baylor College Of Medicine |
Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy
|
|
SG11201703309PA
(en)
*
|
2014-10-31 |
2017-05-30 |
Baylor College Medicine |
Survivin specific t-cell receptor targeting tumor but not t cells
|
|
SG11201703446RA
(en)
|
2014-10-31 |
2017-05-30 |
Abbvie Biotherapeutics Inc |
Anti-cs1 antibodies and antibody drug conjugates
|
|
PT3221359T
(pt)
|
2014-11-17 |
2020-06-23 |
Regeneron Pharma |
Métodos para o tratamento de tumores usando anticorpos biespecíficos cd3xcd20
|
|
PL3226897T3
(pl)
|
2014-12-05 |
2021-08-30 |
Memorial Sloan Kettering Cancer Center |
Przeciwciała do celowania w antygen dojrzewania limfocytów b i sposoby ich zastosowania
|
|
CN113429484A
(zh)
|
2014-12-05 |
2021-09-24 |
纪念斯隆-凯特琳癌症中心 |
靶向g-蛋白偶联受体的抗体和使用方法
|
|
CN113683711A
(zh)
|
2014-12-05 |
2021-11-23 |
纪念斯隆-凯特琳癌症中心 |
靶向g-蛋白偶联受体的嵌合抗原受体及其用途
|
|
WO2016094304A2
(en)
|
2014-12-12 |
2016-06-16 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
CA3224507A1
(en)
|
2014-12-24 |
2016-06-30 |
Autolus Limited |
Cell co-expressing chimeric antigen receptors binding cd19 and cd22
|
|
CA2974453A1
(en)
|
2015-01-23 |
2016-07-28 |
Sanofi |
Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
|
|
KR102329836B1
(ko)
|
2015-01-26 |
2021-11-19 |
셀렉티스 |
암 면역치료를 위한 항-CLL1 특이적 단일-체인 키메라 항원 수용체들(scCARS)
|
|
JP2018507254A
(ja)
|
2015-02-02 |
2018-03-15 |
アイツー ファーマシューティカルズ， インコーポレーテッド |
抗代替軽鎖抗体
|
|
WO2016154047A2
(en)
|
2015-03-20 |
2016-09-29 |
Memorial Sloan-Kettering Cancer Center |
Monoclonal antigen-binding proteins to intracellular oncogene products
|
|
ES2904573T3
(es)
|
2015-03-27 |
2022-04-05 |
Univ Southern California |
Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos
|
|
EP4269601A3
(en)
|
2015-03-27 |
2024-01-10 |
President and Fellows of Harvard College |
Modified t cells and methods of making and using the same
|
|
RU2706582C2
(ru)
|
2015-04-13 |
2019-11-19 |
Пфайзер Инк. |
Химерные антигенные рецепторы, нацеленные на антиген созревания B-клеток
|
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
WO2016176639A1
(en)
|
2015-04-30 |
2016-11-03 |
University Of Southern California |
Secretory tnt car cell immunotherapy
|
|
EA201792441A2
(ru)
|
2015-05-06 |
2018-06-29 |
Янссен Байотек, Инк. |
Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном
|
|
LT3611192T
(lt)
|
2015-05-13 |
2025-06-25 |
Ablynx N.V. |
T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
|
|
IL303905A
(en)
*
|
2015-05-18 |
2023-08-01 |
Tcr2 Therapeutics Inc |
Compositions and methods for TCR programming using fusion proteins
|
|
US9422547B1
(en)
*
|
2015-06-09 |
2016-08-23 |
Gigagen, Inc. |
Recombinant fusion proteins and libraries from immune cell repertoires
|
|
IL281396B
(en)
|
2015-06-09 |
2022-07-01 |
Memorial Sloan Kettering Cancer Center |
T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
|
|
EP4218777A3
(en)
|
2015-08-28 |
2023-08-23 |
The Trustees of the University of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
|
HK1250517A1
(zh)
|
2015-09-17 |
2018-12-21 |
Novartis Ag |
增强功效的car t细胞疗法
|
|
PT3362470T
(pt)
|
2015-10-13 |
2021-12-10 |
Hope City |
Recetores de antigénios quiméricos que contêm um domínio de clorotoxina
|
|
MX2018004721A
(es)
*
|
2015-10-23 |
2018-07-06 |
Eureka Therapeutics Inc |
Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
|
|
BR112018008908A2
(pt)
|
2015-11-02 |
2018-11-27 |
Janssen Pharmaceutica Nv |
anticorpos anti-il1rap, moléculas de ligação ao antígeno biespecíficas que se ligam il1rap e cd3, e seus usos
|
|
CA3018253A1
(en)
|
2016-03-31 |
2017-10-05 |
University Of Southern California |
A highly sensitive and specific luciferase based reporter assay for antigen detection
|
|
SG11201808403SA
(en)
|
2016-04-01 |
2018-10-30 |
Kite Pharma Inc |
Bcma binding molecules and methods of use thereof
|
|
PL3436079T3
(pl)
|
2016-04-01 |
2021-12-20 |
Kite Pharma, Inc. |
Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania
|
|
US12060394B2
(en)
|
2016-04-28 |
2024-08-13 |
The Trustees Of Dartmouth College |
Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
|
|
WO2017192536A1
(en)
*
|
2016-05-02 |
2017-11-09 |
University Of Kansas |
Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
|
|
US11382931B2
(en)
|
2016-07-14 |
2022-07-12 |
University Of Southern California |
Methods and composition for producing and using immune cells and stem cells for cell-based therapies
|
|
CN109890841A
(zh)
|
2016-07-15 |
2019-06-14 |
波赛达治疗公司 |
嵌合抗原受体及使用方法
|
|
WO2018053542A1
(en)
|
2016-09-19 |
2018-03-22 |
University Of Southern California |
Non-radioactive cytotoxicity assays
|
|
CN113543807A
(zh)
|
2019-01-04 |
2021-10-22 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|